Aktuellt
SENASTE
Redeye comments on aXichem’s Q4’21 report. The last quarter of 2021 included some interesting events, and the company is on the right path to start executing on its commercial strategy. We continue to argue that aXichem has an interesting 2022 ahead and see several potential catalysts for the share over the coming months.
LÄS MER
